# Chronic T-Cell {-}

## **Overview of Chronic/Mature T-Cell Leukemia/Lymphoma** {-}

*   **Definition:** A heterogeneous group of lymphoid neoplasms derived from mature (post-thymic) T lymphocytes or natural killer (NK) cells. These disorders can present as leukemias (primarily involving the blood and bone marrow) or lymphomas (primarily involving lymph nodes and other tissues)
*   **Key Features:**
    *   Clonal Proliferation: These are malignant disorders arising from a single, genetically abnormal T cell or NK cell that proliferates uncontrollably
    *   Mature T-Cell Phenotype: The cells express markers characteristic of mature T cells or NK cells (e.g., CD3, CD4, CD8)
    *   Variable Morphology: The cells may have variable size, shape, and nuclear features
    *   Extranodal Involvement: Many of these lymphomas can involve extranodal sites, such as the skin, gastrointestinal tract, and liver
*   **Classification:** The World Health Organization (WHO) classification system is used to categorize these disorders based on clinical, morphological, immunophenotypic, and genetic features. T-cell and NK-cell neoplasms can be broadly classified into:
    *   T-cell lymphomas
    *   T-cell leukemias
    *   NK-cell lymphomas/leukemias

## **Key Disorders** {-}

*   **Large Granular Lymphocytic Leukemia (LGL Leukemia):**
    *   **Definition:** A chronic lymphoproliferative disorder characterized by a sustained increase in large granular lymphocytes (LGLs) in the peripheral blood. There are two main subtypes:
        *   T-LGL Leukemia: More common; derived from cytotoxic T cells (CD3+, CD8+)
        *   NK-LGL Leukemia: Less common; derived from natural killer cells (CD3-, CD56+)
    *   **Pathophysiology:**
        *   Clonal proliferation of LGLs with cytotoxic activity
        *   Associated with STAT3 mutations in many cases
    *   **Clinical Features:**
        *   Often asymptomatic or mild symptoms
        *   Fatigue
        *   Neutropenia: Increased susceptibility to infections
        *   Anemia: Due to pure red cell aplasia (PRCA) or other mechanisms
        *   Splenomegaly (less common)
        *   Association with autoimmune disorders (e.g., rheumatoid arthritis)
    *   **Laboratory Findings:**
        *   CBC:
            *   Lymphocytosis with increased LGLs (typically >2.0 x 10^9/L)
            *   Neutropenia
            *   Anemia
        *   Peripheral Blood Smear:
            *   Large granular lymphocytes with abundant cytoplasm and azurophilic granules
        *   Immunophenotyping:
            *   T-LGL Leukemia: CD3+, CD8+, CD57+, CD16+, TCRαβ+
            *   NK-LGL Leukemia: CD3-, CD56+, CD16+, CD57+, TCR silent
        *   Bone Marrow Examination:
            *   Infiltration of the bone marrow by LGLs
        *   Molecular Testing:
            *   *STAT3* mutations (in some cases)
    *   **Treatment:**
        *   Many patients with asymptomatic LGL leukemia do not require treatment
        *   Immunosuppressive Therapy:
            *   Methotrexate, cyclosporine, corticosteroids
            *   Used to treat cytopenias and autoimmune manifestations
        *   Cyclophosphamide or fludarabine:
            *   May be used in patients with more aggressive disease
        *   Splenectomy:
            *   May be considered in patients with symptomatic splenomegaly or cytopenias

*   **Sézary Syndrome (SS):**
    *   **Definition:** A rare and aggressive form of cutaneous T-cell lymphoma (CTCL) characterized by widespread skin involvement, lymphadenopathy, and the presence of malignant T cells (Sézary cells) in the skin, lymph nodes, and peripheral blood
    *   **Pathophysiology:**
        *   Clonal proliferation of malignant CD4+ T helper cells with skin-homing properties
        *   Cells infiltrate the skin, causing erythroderma (generalized redness and scaling of the skin) and plaques
    *   **Clinical Features:**
        *   Erythroderma: Generalized redness and scaling of the skin
        *   Intense Pruritus (itching)
        *   Lymphadenopathy: Swollen lymph nodes
        *   Sézary cells in the skin and peripheral blood
        *   Hepatosplenomegaly (enlarged liver and spleen)
    *   **Laboratory Findings:**
        *   CBC:
            *   Leukocytosis with lymphocytosis
            *   Eosinophilia
        *   Peripheral Blood Smear:
            *   Sézary cells: Lymphocytes with cerebriform (brain-like) nuclei
        *   Immunophenotyping:
            *   CD3+, CD4+, CD45RO+, CD7- (loss of CD7 is a common finding)
            *   Abnormal T cell receptor expression
        *   Skin Biopsy:
            *   Confirms the diagnosis of CTCL and demonstrates the presence of Sézary cells in the skin
        *   T Cell Receptor (TCR) Gene Rearrangement Studies:
            *   Demonstrates clonality of the T cell population
    *   **Treatment:**
        *   Skin-Directed Therapies:
            *   Topical corticosteroids
            *   Phototherapy (PUVA, UVB)
            *   Topical chemotherapy (e.g., mechlorethamine)
        *   Systemic Therapies:
            *   Extracorporeal photopheresis (ECP): Treats the blood outside the body with ultraviolet light to kill malignant cells
            *   Interferon-alpha
            *   Histone deacetylase (HDAC) inhibitors (e.g., vorinostat, romidepsin)
            *   Chemotherapy (e.g., CHOP)
            *   Mogamulizumab: An anti-CCR4 monoclonal antibody
        *   Stem Cell Transplantation

*   **Hodgkin Lymphoma (HL):**
    *   **Definition:** A type of lymphoma characterized by the presence of Reed-Sternberg cells (large, abnormal lymphocytes)
    *   **Distinction from other lymphomas:** Hodgkin Lymphoma spreads predictably and is more treatable
    *   **Classical Hodgkin Lymphoma (cHL):** The most common subtype, characterized by the presence of Reed-Sternberg cells and their variants in a background of reactive inflammatory cells. Subtypes of cHL include nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted
    *   **Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL):** A less common subtype characterized by lymphocyte-predominant Reed-Sternberg cells (L&H cells) and a different immunophenotype
    *   **Pathophysiology:**
        *   Arises from germinal center or post-germinal center B cells
        *   Reed-Sternberg cells secrete cytokines that attract and activate other immune cells, leading to the formation of a tumor microenvironment
    *   **Clinical Features:**
        *   Painless Lymphadenopathy: Often in the cervical (neck) or mediastinal (chest) region
        *   B Symptoms: Fever, night sweats, weight loss
        *   Pruritus (itching)
        *   Fatigue
    *   **Laboratory Findings:**
        *   CBC: Variable; may be normal or show anemia, leukocytosis, or lymphopenia
        *   Peripheral Blood Smear: Usually normal; may show eosinophilia
        *   Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Often elevated
        *   Lymph Node Biopsy: Essential for diagnosis
            *   Presence of Reed-Sternberg cells (hallmark of HL)
            *   Immunohistochemistry:
                *   Reed-Sternberg cells in cHL: CD30+, CD15+, PAX5+, CD45-
                *   L&H cells in NLPHL: CD20+, BCL6+, CD45+, CD30-, CD15-
        *   Imaging Studies (CT Scan, PET/CT): To stage the disease and assess the extent of involvement
    *   **Treatment:**
        *   Chemotherapy:
            *   ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
            *   BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)
        *   Radiation Therapy:
            *   May be used in combination with chemotherapy
        *   Brentuximab Vedotin:
            *   An anti-CD30 antibody-drug conjugate used for relapsed or refractory HL
        *   Nivolumab and Pembrolizumab:
            *   PD-1 inhibitors used for relapsed or refractory HL
        *   Hematopoietic Stem Cell Transplantation (HSCT):
            *   May be considered for relapsed or refractory disease

## **Important Considerations** {-}

*   These are simplified overviews, and many of these disorders have subtypes and variations
*   Differential diagnosis in this area can be challenging, and often requires integration of clinical, morphological, immunophenotypic, cytogenetic, and molecular data.
*   Treatment is evolving rapidly, with new targeted therapies and immunotherapies becoming available.

## **Key Terms** {-}

*   **Lymphoid Neoplasm:** Malignancy originating from lymphocytes
*   **T Cells:** Lymphocytes responsible for cell-mediated immunity
*   **B Cells:** Lymphocytes responsible for humoral immunity (antibody production)
*   **NK Cells:** Large granular lymphocytes involved in innate immunity
*   **Lymphoma:** Malignancy primarily involving lymph nodes and other lymphoid tissues
*   **Leukemia:** Malignancy primarily involving the bone marrow and peripheral blood
*   **Large Granular Lymphocytic Leukemia (LGL Leukemia):** Leukemia of LGLs
*   **Sézary Syndrome (SS):** Aggressive cutaneous T-cell lymphoma
*   **Hodgkin Lymphoma (HL):** Lymphoma characterized by Reed-Sternberg cells
*   **Reed-Sternberg Cells:** Large, abnormal lymphocytes characteristic of Hodgkin lymphoma
*   **Immunophenotyping:** Identification of cell surface markers using flow cytometry
*   **Cytogenetic Analysis:** The study of chromosomes and their abnormalities
*   **Molecular Testing:** Techniques to detect gene mutations and fusion genes
